Leaders in Pharmaceutical Business Intelligence (LPBI) Group

CHI’s Second Annual Oligonucleotide Discovery and Delivery conference, March 27-28, in Cambridge, MA

Reporter: Aviva Lev-Ari, PhD, RN

 

 

 

Recent advances in nucleic acid medicinal chemistry and delivery have led to the creation of a new generation of oligonucleotide therapies harnessing chemical modifications and conjugations to improve their stability, bioavailability, specificity and potency. These advances, along with a robust development landscape, and several late-stage clinical products poised for approval, have led to a sharp resurgence of interest in the discovery of oligonucleotide-based therapeutics.

Due to the remarkable success of the Inaugural event, Cambridge Healthtech Institute is delighted to host the Second Annual Oligonucleotide Discovery and Delivery conference, March 27-28, in Cambridge, MA. Join leading oligonucleotide developers and discovery scientists to discuss technological and scientific advances in nucleic acid synthesis, medicinal chemistry and delivery, as well as preclinical and clinical findings.

Preliminary Agenda

 

ADVANCES IN OLIGONUCLEOTIDE THERAPEUTICS

GalNAc-Conjugated siRNAs as a New Paradigm in Oligonucleotide Therapeutics

Muthiah (Mano) Manoharan, Ph.D., Senior Vice President, Drug Discovery, Alnylam Pharmaceuticals, Inc.

Talk Title to be Announced

Melissa J. Moore, Ph.D., CSO, Moderna

siRNA Therapeutics for Extrahepatic Indications: Quark’s Case Study

Elena Feinstein, M.D., Ph.D., CSO, Quark Pharmaceuticals

 

EMERGING NUCLEIC ACID DEVELOPMENT PLATFORMS

Small Molecule Nucleic Acid Hybrids (SMNH) Chemistry Platform

R.P. (Kris) Iyer, Ph.D., Co-Founder, CSO, Spring Bank Pharmaceuticals

Third-Generation Antisense (3GA) Technology: Insights into Mechanism of Action

Reina Improgo, Ph.D., Research Scientist, Idera Pharmaceuticals

 

ADVANCES IN RNA THERAPEUTICS AND DELIVERY

Development of Novel Breakthrough Cancer Therapies Based on the Unique Functions of miRNAs

Roel Schaapveld, Ph.D., CEO, InteRNA

Talk Title to be Announced

William Marshall, Ph.D., President and CEO, miRagen Therapeutics

Novel Strategies for Endogenous mRNA Upregulation

Balkrishen (Bal) Bhat, Ph.D., Vice President, Chemistry, RaNA Therapeutics

 

SYNTHESIS AND MEDICINAL CHEMISTRY

Structure Activity Relationships of Trivalent GalNAc Conjugated Antisense Oligonucleotides

Punit Seth, Ph.D., Vice President, Medicinal Chemistry, Ionis Pharmaceuticals

Solid-Phase Purification of Synthetic DNA Sequences and/or Development of 2′-Hydroxy Protecting Groups for Ribonucleosides and Oligoribonucleotides

Serge Beaucage, Ph.D., Chief, Laboratory of Biological Chemistry, CDER, FDA

 

NOVEL AND EMERGING APPROACHES FOR IN VIVO DELIVERY

Talk Title to be Announced

Anastasia Khvorova, Ph.D., Professor, Molecular Medicine, RNA Therapeutics Institute, University of Massachusetts Medical School

A Novel Nano-Medicine Platform for Oligonucleotide Discovery and Delivery

Art Levin, Ph.D., CSO, Avidity

Development of Lipid-Based Oligonucleotide Delivery Systems

Dmitry Samarsky, Ph.D., CSO, Silence Therapeutics

Self-Delivering RNAi Compounds (sd-rxRNA™) for the Treatment of Ocular Disorders

Pamela Pavco, Ph.D., Chief Development Officer, RXi Pharmaceuticals Corp‬.

Development of Three Generations of Nanoparticles for Novel siRNA Therapeutics

Patrick Y. Lu, Ph.D., President & CSO, Sirnaomics, Inc.

 

---

 

For more details on the conference, please contact:

Kip Harry
Senior Conference Director
Cambridge Healthtech Institute
T: (+1) 781-972-5454
E: kharry@healthtech.com

For partnering and sponsorship information, please contact:

Carolyn Benton
Manager, Business Development
Cambridge Healthtech Institute
T: (+1) 781-972-5412
E: cbenton@healthtech.com